Sign Up Today and Learn More About AgomAb Therapeutics Stock
Invest in or calculate the value of your shares in AgomAb Therapeutics or other pre-IPO companies through EquityZen, part of Morgan Stanley.
AgomAb Therapeutics Stock (AGTH)
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
About AgomAb Therapeutics Stock
Founded
2017
Industries
Artificial Intelligence, Software, Data and Analytics
AgomAb Therapeutics Press Mentions
Stay in the know about the latest news on AgomAb Therapeutics
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn’s Disease
biospace • Oct 16, 2026
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
biospace • Oct 11, 2026
Fibrous optics improving in CD as Agomab mulls phase IIb
bioworld • Oct 04, 2026
Agomab’s IPF drug clears first patient test
european-biotechnology • Sep 15, 2026
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
biospace • Sep 15, 2026
AgomAb Therapeutics Management
Leadership team at AgomAb Therapeutics
Co-founder
Virginia Morello
Chief Executive Officer
Tim Knotnerus
Join now and verify your accreditation status to gain access to:
- AgomAb Therapeutics Current Valuation
- AgomAb Therapeutics Stock Price
- AgomAb Therapeutics Management
- Available deals in AgomAb Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- AgomAb Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- AgomAb Therapeutics Revenue and Financials
- AgomAb Therapeutics Highlights
- AgomAb Therapeutics Business Model
- AgomAb Therapeutics Risk Factors
- AgomAb Therapeutics Research Report from SACRA Research
Trading AgomAb Therapeutics Stock
How to invest in AgomAb Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like AgomAb Therapeutics through EquityZen funds. These investments are made available by existing AgomAb Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell AgomAb Therapeutics stock?
Shareholders can sell their AgomAb Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 480K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 57K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
